Melinta antibiotic, Baxdela, achieves top-line results from the second Phase 3 study
by Press Release from Outbreak News Today on (#1DVTC)
Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced last week top-line results from the second Phase 3 study (RX-3341-303 NCT01984684) of Baxdela (delafloxacin), an investigational anionic quinolone in development for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Baxdela met the primary endpoints required ["]
